Bcal Diagnostics Ltd Market Cap ($21.91 Million)
Market Cap & Net Worth: Bcal Diagnostics Ltd (BDX)
Bcal Diagnostics Ltd market cap. Bcal Diagnostics Ltd (AU:BDX) has a market capitalization of $21.91 Million (AU$30.97 Million) as of November 1, 2026. Listed on the AU stock exchange, this Australia-based company holds position #24681 globally and #1001 in its home market, demonstrating a 12.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bcal Diagnostics Ltd's stock price AU$0.08 by its total outstanding shares 368683291 (368.68 Million). Also see cash flow conversion of Bcal Diagnostics Ltd for how efficiently the company converts equity into cash flow.
Bcal Diagnostics Ltd Market Cap History (2021–2026)
Bcal Diagnostics Ltd market cap history from 2021 to 2026. Data shows change from $32.61 Million to $21.91 Million (-18.66% CAGR). Check latest Bcal Diagnostics Ltd stock price today for real-time trading data and today's change.
Bcal Diagnostics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bcal Diagnostics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Bcal Diagnostics Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
150.08x
Bcal Diagnostics Ltd's market cap is 150.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $32.61 Million | $718.67K | -$3.39 Million | 45.37x | N/A |
| 2022 | $15.65 Million | $2.79 Million | -$5.06 Million | 5.61x | N/A |
| 2023 | $25.83 Million | $3.10 Million | -$6.40 Million | 8.34x | N/A |
| 2024 | $25.30 Million | $21.64K | -$7.24 Million | 1169.48x | N/A |
| 2025 | $27.39 Million | $182.51K | -$7.37 Million | 150.08x | N/A |
Competitor Companies of BDX by Market Capitalization
Companies near Bcal Diagnostics Ltd in the global market cap rankings as of November 1, 2026. Also see Bcal Diagnostics Ltd assets under control for a full breakdown of the balance sheet.
Key companies related to Bcal Diagnostics Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #143 globally with a market cap of $164.04 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #480 globally with a market cap of $56.33 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #530 globally with a market cap of $51.40 Billion USD ( CN¥351.23 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $697.00 |
| #143 | Danaher Corporation | NYSE:DHR | $164.04 Billion | $232.23 |
| #480 | Natera Inc | NASDAQ:NTRA | $56.33 Billion | $414.30 |
| #530 | WuXi AppTec Co Ltd | SHG:603259 | $51.40 Billion | CN¥142.01 |
Market Capitalization of Bcal Diagnostics Ltd (2021–2026)
Market capitalization of Bcal Diagnostics Ltd from 2021 to today. Between 2021 and today, Bcal Diagnostics Ltd's market cap moved from $32.61 Million to $ 21.91 Million, with a yearly change of -18.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$21.91 Million | -20.00% |
| 2025 | AU$27.39 Million | +8.25% |
| 2024 | AU$25.30 Million | -2.02% |
| 2023 | AU$25.83 Million | +65.00% |
| 2022 | AU$15.65 Million | -52.00% |
| 2021 | AU$32.61 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Bcal Diagnostics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.91 Million USD |
| MoneyControl | $21.91 Million USD |
| MarketWatch | $21.91 Million USD |
| marketcap.company | $21.91 Million USD |
| Reuters | $21.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bcal Diagnostics Ltd
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 an… Read more